Investors - Media Releases

Stay Informed

2010 2009 2008 2007 2006 2005 2004 2003

Back to list

April 30, 2010

Results of the Annual General Meeting of mondoBIOTECH holding AG (SIX: RARE)

Stans, Switzerland – April 30, 2010 - At the Annual General Meeting on April 30, 2010, mondoBIOTECH Holding AG Shareholders unanimously approved the annual report and the group financial statements 2009, agreed with 99.99% of the voting rights to offset the loss for the year against reserves and the further proposed transfer form general to free reserves, discharged with 96.8% of the voting rights the member of the Board of Directors and the Group Executive Committee for 2009, reaffirmed with 99.99% of the voting rights PricewaterhouseCoopers as auditor and approved with 99.99% of the voting rights the amendment of the article 3a of the articles of incorporation inherent the extension of the authorization to issue new shares out of authorized share capital from currently 20 February 2011 to 30 April 2012 while leaving the number of authorized new shares unchanged. 73% of the voting rights were represented at the meeting. Elections to the Board of Directors The Annual General Meeting has approved the election of the following Directors: Re-election Prinz Michael von und zu Liechtenstein Fabio Cavalli Vera Cavalli Prof. Dr. Robert Huber Prof. Michael Alan Keller Prof. Dr. Thomas Cerny New elections: Prof. Roland M. du Bois Prof. du Bois is Professor of Medicine at National Jewish Health in Denver, Colorado and at Imperial College, London. He is also a member of the American Thoracic Society, American College of Chest Physicians, European Respiratory Society, and British Thoracic Society. His research areas are the genetics of chronic fibrosing lung disease, cellular and molecular biology, autoimmunity/rheumatology, environmental and occupational diseases, and interstitial lung diseases (ILD)/pulmonary fibrosis. In Denver, Prof. du Bois works on a variety of programmes including: the development of a rheumatological lung disease program to define the clinical and molecular phenotypes of lung disease that occur in rheumatological disease; a program of research into hypersensitivity pneumonitis across the divisions of Pulmonary Medicine and Occupational and Environmental Health Sciences; studies into the genetic background to fibrosing and granulomatous lung disease in the Center for Genes, Environment, and Health. In each of these endeavors, a common goal is to bridge basic and clinical science into a bonded multidisciplinary translational research program with the patient at the core. Robert Edward Patterson Mr. Patterson is an experienced and highly regarded venture capitalist based in Silicon Valley. In addition to receiving a Bachelor of Arts degree in Physics from the University of California at Los Angeles, Mr. Patterson served as a Lieutenant Commander in the U.S. Navy, completing extensive training in nuclear physics as pertaining to pressurized water thermal neutron reactors, propulsion engineering, nuclear weapons, strategic submarine operations and military intelligence. Mr. Patterson attended the Stanford University School of Law, receiving his Juris Doctor in 1972. He was the Inaugural Fellow of the Center for Private Equity and Entrepreneurship at the Tuck School of Business at Dartmouth College. Mr. Patterson was a corporate lawyer with a 35-year tenure at Squire, Sanders & Dempsey, specialized in high technology venture investing and international business of all types. Mr. Patterson’s long and illustrious career includes serving as an initial board member of numerous biotechnology and pharmaceutical corporations, including Sequenom (NASDAQ), Synzyme Technologies LLC, Procyte Corporation (NASDAQ), Medical Research Inc., MARC Analysis Research Corporation and InPro Biotechnology Inc. Mr. Patterson was a founding partner of Peninsula Ventures, and President of its predecessor U.S. venture fund, Thompson Clive Inc., investing in biotechnology companies and other businesses. Current board directorships include, among others, Factor Technology Group, SynZyme Technogies LLC and Sumida Corporation (Tokyo Stock Exchange-Tier One). Graf Francis von Seilern-Aspang Graf Francis von Seilern-Aspang is CEO of Industrie - und Finanzkontor Etablissement, a financial services institution based in the Principality of Liechtenstein. Born in 1954, his international professional career has included senior management positions in the fields of trust administration, insurance and asset management in Spain, Austria, Italy, Switzerland, Liechtenstein and the United Kingdom. Prof. Geoffrey West Prof. West is Distinguished Professor and former President of the Santa Fe Institute (SFI). He is a visiting Professor at Imperial College in London and an associate Fellow at the Said Business School, Oxford University. Prior to joining the Santa Fe Institute as a Distinguished Professor in 2003, he was the leader and founder of the high energy physics group at Los Alamos National Laboratory, where he is one of only approximately ten Senior Fellows. He received his BA from Cambridge University in 1961 and his doctorate from Stanford University in 1966, where he returned in 1970 to become a member of the faculty. He was named SFI President in July 2005. Geoffrey West is a theoretical physicist whose primary interests have been in fundamental questions in physics and biology, ranging from the elementary particles, their interactions and cosmological implications to universal scaling laws and a unifying quantitative framework of biology. His research areas include metabolic rate, growth, aging, sleep, cancer, and ecosystems. He has recently been working on extensions to an underlying theory of cities, companies and long-term sustainability; problems include rates of growth and innovation, and the accelerating pace of life. He is the author of several books and a Fellow of the American Physical Society. Among recent awards are the Mercer Prize, Ecological Society of America; the Weldon Memorial Prize for Mathematical Biology and the Glenn Award for Aging research. His work was selected as a breakthrough idea of 2007 by Harvard Business Review and he was selected for Time magazine's list of "100 Most Influential People in the World" in 2006. Representative of the common Shareholders in accordance with article 709 of the Swiss Code of obligations and article 16 paragraph 4 of the Articles of Incorporation as a member of the Board of directors: Ruggero Gramatica With over 17 years in his industry, Ruggero Gramatica has extensive depth and breadth of experience in start-ups and company turnaround particularly in the services industry. Bringing strategic leadership as well as technological and operational expertise to bear, he has contributed to the growth and expansion of 6 successful start-up companies throughout US and Europe. Currently Ruggero is founder and CEO of Chancery Business Consulting, an independent boutique advisory company specialized in the definition and execution of business development and corporate finance transactions, such reorganizations of groups’ structures, corporate finance, strategy definition and turnaround. At Chancery BC Ruggero’s expertise provides unique products and services to help clients capture new opportunities, reduce dangers and risks, and simplify complexity in their business activity. From working capital strategies for small to medium enterprises, to implementing operational processes and execution, Ruggero is able to deliver effective and measurable results. Expertise: M&A, PE & VC, Turnaround, Project Finance, Due Diligence Business Planning and Strategic Advisory. Management Consulting in areas such as Finance, HR, Strategy, Mktg, Operations, Procurement Program Mgmt. Industry focus: TMT, Financial Service, Energy, Technology, Government & Public Services, Health Care, International Development, Manufacturing Prior to his work in Chancery BC, Ruggero Gramatica was one of the founders and Chief Executive Officer of OnTelecoms SA and remains Executive Vice Chairman and Board Member of both the operating and holding companies. OnTelecoms was founded in 2006 and since then has built a broadband triple play network covering 1.6m households in Greece. It provides both consumer and business services and is the fastest growing Operator in the country. The company turnover is currently €90m p.a. and employ 300. Prior to OnTelecoms, Ruggero was Founder and Chief Executive Officer of NextEdge Partners - an international consultancy firm set up in 2004 to provide advisory services and consultancy to Communication Providers across Europe.  The company specialized in Mergers and Acquisitions and major ventures included the acquisition of Bulldog Communications and Monaco Telecoms for Cable and Wireless plc and the sartup of Erenis and its sale. Consultancy clients included Swisscom, Deutsche Telecom and Cable and Wireless. Work undertaken ranged from strategy to operational management. In that capacity Ruggero’s served Bulldog Communications, a Cable & Wireless broadband subsidiary, first as acting Chief Operating Officer and later as Chief Strategy Officer where in two years he helped to manage the turnaround of young company to a competitive player in the U.K. broadband market. Before establishing his own successful consulting company, Ruggero co-founded in 1999 FastWeb, an innovative Italian telecommunications operator that pioneered 'triple-play' on fiber-to-the-home networks and xDSL access technology. In this start up, Ruggero conceptualized, developed and launched the first large-scale multi channel pay-TV service over IP. This enabled customers to access a full entertainment experience and radically enlarged the company's initial strategy of offering solely Video-on-Demand services. FastWeb's parent company (e.Biscom) of which Ruggero was a founder, was able to raise over 1.6 billion Euros in their Initial Public Offering. FastWeb was subsequently sold to SwissCom in 2007 for 3.6 billion Euros. Within e.Biscom Ruggero sat on the Board of Directors as Chairman and Vice-Chairman of some of the participated and controlled companies, including e.Bismedia, the content packager company providing content for the TV business. Ruggero has contributed to the growth and expansion of 6 successful start-up companies (including Fastweb, Covad Communications, PacificBell, Omnitel-Vodafone the second wireless TelCo in Italy, Bulldog and OnTelecoms) contributing to the establishment of DSL Broadband and GSM cellular services in the United States and across Europe. Of Ruggero's 17+ years experience, he has spent 6 years in the United States, 2 years in London, 2 years in Greece and 7 years based in Italy. Ruggero is currently pursuing a part time PhD in Applied Mathematics at King’s College London, he holds an MBA from the University of Chicago Graduate Business School, an Engineering degree from the Politecnico di Milano University and a certificate in Quantitative Finance. “We thank all our shareholders for their confidence in the Board of Directors and in the Company” said Prinz Michael von Liechtenstein, Chairman of the Board of Directors of mondoBIOTECH holding AG. About Mondobiotech mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians, patients and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases. For further information please contact: mondoBIOTECH holding AG Das Kloster Mürgstrasse 18 CH-6370 Stans-Switzerland Tel.: +41 (0) 840 200 010 Fax: +41 (0) 840 200 011 investor@mondobiotech.com www.mondobiotech.com Disclaimer The foregoing release may contain forward-looking statements. The words “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG’s forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward- looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Personal Information This email is from mondoBIOTECH holding AG. The email and any files transmitted with it are intended solely for the use of the individual or entity to which they are addressed. Any unauthorized dissemination or copying of this email or its attachments, is strictly prohibited and may be illegal. If you have received the email in error please delete it from your system. Download the Newsletter in pdf format

Back to list